The WFH Humanitarian Aid Program aims to improve the lack of access to care and treatment for people with inherited bleeding disorders in developing countries, and is a critically important endeavour for the bleeding disorders community. Today, the World Federation of Hemophilia (WFH) and WFH USA are proud to announce that Roche has joined the WFH Humanitarian Aid Program.
The commitment of the Roche Group will consist of a donation of emicizumab, a prophylactic treatment for hemophilia A, and funding to deliver the WFH Humanitarian Aid Program’s integrated care development training to ensure that local infrastructure and medical expertise are available to use the donated emicizumab in the most efficient and effective way possible.
The donation will provide prophylactic treatment with emicizumab to as many as 1,000 people with hemophilia A in developing countries over the course of five years. The treatment focus will be on high-need patients, such as people with factor VIII inhibitors and children without factor VIII inhibitors. The Roche donation will bring prophylactic treatment—the standard of care for haemophilia A to prevent bleeds—to the developing world, which will have a significant impact on the local bleeding disorders communities in those countries.